Abstract
The aim of this study was to verify the capability of an MIRD formula-based dosimetric method to predict radioiodine kinetics (fraction of administered iodine transferred to the thyroid, U0, and effective clearance rate, λeff) and absorbed dose after oral therapeutic 131I administration. The method is based on 123I intravenous administration and five subsequent gamma camera measured uptake values determined separately on different structures within the thyroid. Another dosimetric method based on only the 123I 24-h uptake and a fixed λeff value was also considered. Eighty-nine hyperthyroid patients (10 with Graves' disease and 79 with autonomously functioning nodules) were studied and 132 thyroidal structures were evaluated. The mean time interval between dosimetry and therapy was 20±10d. Uptake values were measured at 2, 4, 24, 48, and 120 h during dosimetry and at 2, 4, 24, 48, 96, and 168 h during therapy. The value 0.125d-1 was chosen in the fixed-λeff method. The planned doses to the target ranged from 120 to 250 Gy depending on the type and severity of hyperthyroidism. The following significant correlations between therapeutic and dosimetric parameters were found: U0ther=0.88U0dos (r=0.97, peffther =1.01λeffdos (r=0.85, pestimated=0.85Dplanned (r=0.88, p0ther and U0dos ranged from -44 to 32% and between λeffther and λeffdos from -32 to 48%. U0ther was lower than U0dos in 74% of cases: this can be explained by the self-stunning effect of 131I therapeutic activity that produced a dose of about 20 Gy with a maximum dose rate of 0.6 Gy/h over the initial 24-48 h. The differences, ΔD, between the estimated and the planned doses ranged from -42% (-87 Gy) to 32% (59 Gy); in 73% of cases the difference was within ±35 Gy. Greater discrepancies were found with the fixed-λeff method, in which ΔD ranged from -69 to 95% (-202 to 88 Gy, respectively). In hyperthyroid patients, the five uptake value dosimetric method is able to predict with a good agreement the radioiodine kinetics and the dose after the therapeutic administration in about 73% of the analyzed thyroid structures. The fixed-λeff method is less reliable.
| Original language | English |
|---|---|
| Pages (from-to) | 2860-2867 |
| Number of pages | 8 |
| Journal | Medical Physics |
| Volume | 33 |
| Issue number | 8 |
| DOIs | |
| Publication status | Published - 2006 |
Fingerprint
Keywords
- Dosimetry and therapy comparison
- Hyperthyroidism
- Radioiodine treatment
ASJC Scopus subject areas
- Biophysics
Cite this
Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients. / Canzi, Cristina; Zito, Felicia; Voltini, Franco; Reschini, Eugenio; Gerundini, Paolo.
In: Medical Physics, Vol. 33, No. 8, 2006, p. 2860-2867.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Verification of the agreement of two dosimetric methods with radioiodine therapy in hyperthyroid patients
AU - Canzi, Cristina
AU - Zito, Felicia
AU - Voltini, Franco
AU - Reschini, Eugenio
AU - Gerundini, Paolo
PY - 2006
Y1 - 2006
N2 - The aim of this study was to verify the capability of an MIRD formula-based dosimetric method to predict radioiodine kinetics (fraction of administered iodine transferred to the thyroid, U0, and effective clearance rate, λeff) and absorbed dose after oral therapeutic 131I administration. The method is based on 123I intravenous administration and five subsequent gamma camera measured uptake values determined separately on different structures within the thyroid. Another dosimetric method based on only the 123I 24-h uptake and a fixed λeff value was also considered. Eighty-nine hyperthyroid patients (10 with Graves' disease and 79 with autonomously functioning nodules) were studied and 132 thyroidal structures were evaluated. The mean time interval between dosimetry and therapy was 20±10d. Uptake values were measured at 2, 4, 24, 48, and 120 h during dosimetry and at 2, 4, 24, 48, 96, and 168 h during therapy. The value 0.125d-1 was chosen in the fixed-λeff method. The planned doses to the target ranged from 120 to 250 Gy depending on the type and severity of hyperthyroidism. The following significant correlations between therapeutic and dosimetric parameters were found: U0ther=0.88U0dos (r=0.97, peffther =1.01λeffdos (r=0.85, pestimated=0.85Dplanned (r=0.88, p0ther and U0dos ranged from -44 to 32% and between λeffther and λeffdos from -32 to 48%. U0ther was lower than U0dos in 74% of cases: this can be explained by the self-stunning effect of 131I therapeutic activity that produced a dose of about 20 Gy with a maximum dose rate of 0.6 Gy/h over the initial 24-48 h. The differences, ΔD, between the estimated and the planned doses ranged from -42% (-87 Gy) to 32% (59 Gy); in 73% of cases the difference was within ±35 Gy. Greater discrepancies were found with the fixed-λeff method, in which ΔD ranged from -69 to 95% (-202 to 88 Gy, respectively). In hyperthyroid patients, the five uptake value dosimetric method is able to predict with a good agreement the radioiodine kinetics and the dose after the therapeutic administration in about 73% of the analyzed thyroid structures. The fixed-λeff method is less reliable.
AB - The aim of this study was to verify the capability of an MIRD formula-based dosimetric method to predict radioiodine kinetics (fraction of administered iodine transferred to the thyroid, U0, and effective clearance rate, λeff) and absorbed dose after oral therapeutic 131I administration. The method is based on 123I intravenous administration and five subsequent gamma camera measured uptake values determined separately on different structures within the thyroid. Another dosimetric method based on only the 123I 24-h uptake and a fixed λeff value was also considered. Eighty-nine hyperthyroid patients (10 with Graves' disease and 79 with autonomously functioning nodules) were studied and 132 thyroidal structures were evaluated. The mean time interval between dosimetry and therapy was 20±10d. Uptake values were measured at 2, 4, 24, 48, and 120 h during dosimetry and at 2, 4, 24, 48, 96, and 168 h during therapy. The value 0.125d-1 was chosen in the fixed-λeff method. The planned doses to the target ranged from 120 to 250 Gy depending on the type and severity of hyperthyroidism. The following significant correlations between therapeutic and dosimetric parameters were found: U0ther=0.88U0dos (r=0.97, peffther =1.01λeffdos (r=0.85, pestimated=0.85Dplanned (r=0.88, p0ther and U0dos ranged from -44 to 32% and between λeffther and λeffdos from -32 to 48%. U0ther was lower than U0dos in 74% of cases: this can be explained by the self-stunning effect of 131I therapeutic activity that produced a dose of about 20 Gy with a maximum dose rate of 0.6 Gy/h over the initial 24-48 h. The differences, ΔD, between the estimated and the planned doses ranged from -42% (-87 Gy) to 32% (59 Gy); in 73% of cases the difference was within ±35 Gy. Greater discrepancies were found with the fixed-λeff method, in which ΔD ranged from -69 to 95% (-202 to 88 Gy, respectively). In hyperthyroid patients, the five uptake value dosimetric method is able to predict with a good agreement the radioiodine kinetics and the dose after the therapeutic administration in about 73% of the analyzed thyroid structures. The fixed-λeff method is less reliable.
KW - Dosimetry and therapy comparison
KW - Hyperthyroidism
KW - Radioiodine treatment
UR - http://www.scopus.com/inward/record.url?scp=33746638745&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746638745&partnerID=8YFLogxK
U2 - 10.1118/1.2210564
DO - 10.1118/1.2210564
M3 - Article
C2 - 16964862
AN - SCOPUS:33746638745
VL - 33
SP - 2860
EP - 2867
JO - Medical Physics
JF - Medical Physics
SN - 0094-2405
IS - 8
ER -